Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses

Hepatocellular carcinoma (HCC) is one of the leading causes of global cancer-related deaths. The majority of patients present with advanced disease and current medical therapy only prolongs survival by a few months.1 HCC occurs on the background of chronic liver disease in more than 90% of cases and is a paradigm for inflammation-induced cancer where the tumour microenvironment (TME) is characterised by ongoing metabolic stress and an immunosuppressive environment.2 This has led to significant interest in assessing whether immunotherapy could be an effective approach to combat this cancer.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research